A First-In-Human Study of BLZ-100 (Tozuleristide) Demonstrates Tolerability and Fluorescence Contrast in Skin Cancer
April 2018
in “
Journal of Investigative Dermatology
”
Studysummary In this first-in-human study, BLZ-100, an intraoperative fluorescent imaging agent, was administered to 21 patients before skin cancer surgery and was found to be well tolerated without serious adverse effects, suggesting its potential to help distinguish cancerous from non-cancerous tissue based on fluorescence.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jidonline.org →